logo-loader
viewSareum Holdings PLC

Cancer drug payment nudges Sareum Holdings into maiden profit

Tim Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells Proactive the company's posted a maiden profit after receiving the first payments from licensing lead product, a Chk1 inhibitor cancer candidate, to Sierra Oncology.

Quick facts: Sareum Holdings PLC

Price: 0.4 GBX

AIM:SAR
Market: AIM
Market Cap: £12.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls Bears & Brokers: Martin Place Securities Barry Dawes on a new uptick...

Martin Place Securities executive chairman Barry Dawes speaks to Proactive about gold jumping nicely to pass through US$1600 an ounce, and silver also moving upwards through US$18. Dawes talks about the markets and why the US dollar is strong while the euro is weak. He also covers this...

3 hours, 20 minutes ago

2 min read